Development of tinea corporis in a Japanese patient with atopic dermatitis under treatment with upadacitinib in a real‐world clinical setting: Possible contribution of the suppression of Th17
We present a rare case of a patient with AD who developed tinea corporis during upadacitinib treatment in a real‐world clinical setting. We hypothesized that the suppressive effect of Th17 immunity by upadacitinib possibly has contributed to the development of tinea corporis.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Online Access: | https://doi.org/10.1002/cia2.12258 |